Related Experiment Videos
Chemotherapy for metastatic bladder cancer.
1Department of Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.
Hematology/Oncology Clinics of North America
|February 1, 1992
Summary
Chemotherapy for metastatic bladder cancer shows high response rates but modest survival benefits. Current treatments serve as comparisons for developing more effective future therapies.
Area of Science:
- Oncology
- Urothelial Carcinomas
Background:
- Chemotherapy is a primary treatment for metastatic bladder cancer.
- Combination regimens like M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) and CMV (cisplatin, methotrexate, and vinblastine) have been investigated.
Purpose of the Study:
- To evaluate the efficacy of current chemotherapy regimens for metastatic bladder cancer.
- To determine if existing treatments represent the optimal standard of care or benchmarks for future research.
Main Methods:
- Review of acquired data on chemotherapy use in metastatic bladder cancer over the past decade.
- Analysis of response rates and survival impact of combination chemotherapy regimens.
Main Results:
- Combination chemotherapy regimens, including M-VAC and CMV, achieve high objective response rates.
- Despite high response rates, the overall impact of these chemotherapy regimens on patient survival has been modest.
Conclusions:
- Current chemotherapy regimens for metastatic bladder cancer, while effective in generating responses, do not significantly improve survival.
- Existing treatment protocols should be viewed as standards for comparison rather than definitive standards of care, highlighting the need for improved therapeutic strategies.